Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ScTIL210 in Melanoma
NCT04357509Phase 1Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- May 2020
- Primary completion
- Dec 2021
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ScTIL in acral lentiginous melanoma (ALM) and mucosal melanoma (MM), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Objective Response Rate at 24 weeks. Status: unknown.
02
Drugs
ScTIL
03
Conditions
acral lentiginous melanoma (ALM)mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT04357509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04357509.